Crossject to present at Biotech Showcase on January 9 at 16:30 PT
January 09 2024 - 10:21AM
Crossject to present at Biotech Showcase on January 9 at 16:30 PT
Press Release
Crossject to present at Biotech Showcase
on January 9 at 16:30 PT
Dijon, France, January 9, 2024 -- Crossject (ISIN:
FR0011716265; Euronext: ALCJ), a specialty pharma company
developing needle-free auto-injectors for emergency
situations, will hold a presentation at the Biotech
Showcase conference, being held in San Francisco, on January 9,
2024 at 16:30 PT (January 10, 01:30 CET).
Details of the presentation:
Time: Tuesday, January 9, 2024, 16:30 PT
Track: Yosemite C (Ballroom Level)
Webcast:
https://event.webcasts.com/starthere.jsp?ei=1651413&tp_key=8efdfbf518
A webcast replay will be available two hours after the end of
the presentation.
About Crossject
Crossject SA (Euronext: ALCJ;
www.crossject.com) is an emerging specialty pharma companybased in
France and the U.S. It is in advanced regulatory development for
ZEPIZURE®, anepileptic rescue therapy, for which it was awarded a
$60 million contract with the U.S.Biomedical Advanced Research and
Development Authority (BARDA). ZEPIZURE® is based on the Company’s
award-winning needle-free autoinjector ZENEO®, which is designed to
enable patients and untrained caregivers to easily and instantly
deliver emergency medication via intramuscular injection on bare
skin or even through clothing. The Company’s other products in
development include rescue therapies for allergic shocks, adrenal
insufficiencies, opioid overdose and asthma attacks.
For further information, please contact:
Investors Natasha DrapeauCohesion Bureau+41 76 823
75 27natasha.drapeau@cohesionbureau.com |
MediaSophie BaumontCohesion Bureau+33 6 27 74 74
49sophie.baumont@cohesionbureau.com |
|
- Crossject_Press release SF Presentation 09012024
Crossject (EU:ALCJ)
Historical Stock Chart
From Apr 2024 to May 2024
Crossject (EU:ALCJ)
Historical Stock Chart
From May 2023 to May 2024